Based on current preclinical and clinical data, the inhibition of the PD-1/PD-L1 pathway is the most explored immunotherapy strategy in metastatic NSCLC [8, 60, 61, 67–69]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.